Ipigrix (Ipidacrine Hydrochloride)

Ipigrix, an acetylcholinesterase inhibitor, is used to address cognitive deficits associated with several neurological disorders.

• Alzheimer's disease: improves memory and overall cognitive performance in patients with mild to moderate disease.
• Vascular dementia: supports attention and executive function in individuals with cerebrovascular‑related cognitive decline.
• Post‑stroke cognitive impairment: aids recovery of mental functions after cerebral ischemic events.
• Age‑related cognitive decline: helps maintain mental acuity in older adults.
• Traumatic brain injury: may enhance cognitive recovery during rehabilitation.

• Ipidacrine Hydrochloride reversibly binds to the active site of acetylcholinesterase, preventing the enzymatic breakdown of acetylcholine in synaptic clefts. By sustaining higher acetylcholine concentrations, it enhances cholinergic neurotransmission in the central nervous system, which is associated with improved learning, memory, and attention processes. The inhibition is competitive and dose‑dependent, allowing normal enzyme activity to resume as drug levels decline. This pharmacodynamic profile contributes to a relatively rapid onset of action after intramuscular injection.

Common and serious adverse reactions have been reported with intramuscular Ipidacrine Hydrochloride.

Common Side Effects

• Nausea: mild to moderate stomach upset.
• Headache: transient cranial discomfort.
• Dizziness: occasional light‑headedness.
• Fatigue: general tiredness.
• Gastrointestinal discomfort: abdominal pain or dyspepsia.
• Increased salivation: mild drooling.

Serious or Rare Side Effects

• Hepatotoxicity: elevated liver enzymes or liver injury.
• Severe allergic reaction: rash, itching, swelling, or anaphylaxis.
• Cardiac arrhythmia: irregular heartbeat, especially in patients with pre‑existing heart disease.
• Seizures: rare convulsive episodes.
• Thrombocytopenia: low platelet count leading to bleeding risk.

When using Ipigrix, several precautionary measures should be observed to ensure patient safety.

• Renal impairment: monitor kidney function and adjust treatment as necessary.
• Hepatic disease: assess liver enzymes before initiation and during therapy.
• Cardiac conditions: observe for arrhythmias or heart rate changes.
• Concomitant cholinergic drugs: avoid excessive cholinergic activity by reviewing concomitant medications.
• Pregnancy and lactation: prescribe only if potential benefit outweighs risk to mother and fetus.
• Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Ipidacrine Hydrochloride may interact with other medicines; awareness of major and moderate interactions helps manage risk.

Major Interactions (Avoid)

• Anticholinergic agents: antagonize therapeutic effect by reducing acetylcholine activity.
• Other acetylcholinesterase inhibitors: additive inhibition can lead to cholinergic toxicity.
• Organophosphate exposure: heightened cholinergic response may cause severe toxicity.

Moderate Interactions (Monitor Closely)

• CYP450 inhibitors (e.g., erythromycin, fluconazole): may increase plasma levels of Ipidacrine.
• CYP450 inducers (e.g., rifampicin, carbamazepine): may reduce drug concentration and effectiveness.
• Diuretics: can alter electrolyte balance, affecting cholinergic function.